Psychological aspects of health behaviours in NAFLD

Prof. Maya Balakrishnan (USA) discusses the importance of the behavioural psychology in the field of non-alcoholic fatty liver disease (NAFLD). Data shows that NAFLD patients had adverse cognitive behavioural profiles and some have co-existing mental illnesses. Therefore healthcare professionals need to implement targeted intervention strategies in order to ensure behaviour change. She further says that standard of care is ineffective however by intervening on cognitive determinants we can promote healthy behaviours and weight loss. For clinicians, Prof. Balakrishnan mentions that we need to translate cognitive strategies and implement obesity behavioural research to patients with NAFLD. 

Read More

NASH Management in 2022

Prof. Stephen Harrison (USA) discusses state of the art management of non-alcoholic steatohepatitis (NASH) in 2022. He focuses on the benefits of lifestyle recommendations, including nutrition and exercise. He shows that weight loss is associated with NASH resolution and fibrosis regression over time following bariatric surgery in patients with severe obesity and NASH. He mentions that NASH progression to clinical outcomes may take time, hence trials for NASH treatment look at surrogate outcomes (histologic endpoints) which are NASH resolution and/or fibrosis improvement approved by the FDA. Further he explores if NASH is reversible and also looks into the potential targets for NASH treatment.

Read More


This video presents a comprehensive review of non-alcoholic fatty liver disease (NAFLD) & non-alcoholic steatohepatitis (NASH), delivered by international experts with a multidisciplinary approach: Dr. Maarten Tushuizen, Prof. A.G (Onno) Holleboom, and Prof. Sven Francque, along with chair, Prof. Stefan Anker. They review the epidemiology of NAFLD / NASH, its increasing prevalence rates, and discuss current best practices to improve patient outcomes.

Read More


In this video, Prof. Sven Francque (Belgium) discusses how vascular mechanisms contribute to non-alcoholic fatty liver disease (NAFLD) and how non-alcoholic steatohepatitis (NASH) contributes to cardiovascular disease (CVD). He also mentions that drugs used to prevent/treat CVD and NAFLD/NASH are safe and those that are used to prevent/treat CVD can have some benefits for NAFLD.

Read More
A.G. (Onno) Holleboom Netherlands

Getting to the heart of nafld/nash – the cvd perspective (part 2)

Prof. Onno Holleboom reviews the strong co-occurence of non-alcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular (CVD) disease in this video along with joint pathophysiological pathways and its shared drivers. He further looks into NAFLD and its relationships and effects with atherosclerotic CVD and heart failure. For clinicians, he provides an analyses of the management and diagnosis options for advanced NAFLD.  

Read More
Dr. Maarten E Tushuizen


Prof. Maarten Tushuizen provides a comprehensive review on Non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) and why it is a multisystem disease and further goes on to evaluate their connection to type 2 diabetes mellitus (T2DM) and cardiovascular disease. He also delves into the next steps of managing and diagnosing NASH and NAFLD.

Read More

5Th Global Nash Congress

This slides set presents a detailed review of vascular alterations in non-alcoholic steatohepatitis (NASH) and NASH cirrhosis delivered by Professor Francque, MD, PhD. He highlights that non-fibrotic non-alcoholic fatty liver disease (NAFLD) is accompanied by a significant rise in portal pressure. Professor Francque, also explains the effects of intrahepatic vascular resistance increase in NAFLD. To the clinicians, he provides various patient studies, statistics and clinical data on the subject.

Read More
pannash Webinar -2

Going beyond the liver in NAFLD/NASH: hepatologist’s / endocrinologist’s perspective

This multidisciplinary discussion on the diabetologist’s and hepatologist’s perspectives of non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH), involves international experts, Dr. Maarten Tushuizen, Prof. A.G (Onno) Holleboom and Prof. Christophe Moreno, together with the chair, Professor Manuel Castor Cabezas. The review addresses NAFLD as a multisystem disease, its epidemiology globally and the significance of developing multidisciplinary care paths.

Read More

Non-Invasive Evaluation of NAFLD Severity

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are a leading cause of liver diseases worldwide, including hepatocellular carcinoma (HCC). In this review on non-invasive evaluation, Prof. Jérôme Boursier, France, presents a meta analysis focusing on the identification of patients with high risk profile and in need of specific management. Dr. Boursier reviews the two major families of non-invasive tests and discusses the sequential use of tests recommended in the EASL guidelines 2021.

Read More

NIT for screening, referral & diagnosis of NAFLD

Liver fibrosis is the major driver in liver disease progression. Prof. Romero-Gómez, Spain, reviews on NoninvasiveTests – NITs for screening, referral, and diagnosis of nonalcoholic fatty liver disease. He addresses the EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis (a 2021 update). Further, he reviews the detection methods of fibrosis and emphasizes on the importance of introducing educational and communication tools to increase awareness.

Read More